Innate Pharma (NASDAQ:IPHA) Earns “Buy” Rating from BTIG Research

Innate Pharma (NASDAQ:IPHA)‘s stock had its “buy” rating reaffirmed by equities researchers at BTIG Research in a note issued to investors on Thursday, September 17th, Benzinga reports. They presently have a $9.00 price objective on the stock. BTIG Research’s target price would suggest a potential upside of 429.41% from the stock’s previous close.

IPHA has been the subject of several other reports. Weiss Ratings raised Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 26th. Leerink Partners raised shares of Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price target on the stock in a research note on Tuesday, August 11th. UBS Group reaffirmed a “buy” rating on shares of Innate Pharma in a research note on Tuesday, August 11th. Citigroup raised Innate Pharma from a “buy” rating to an “outperform” rating in a research note on Tuesday, August 11th. Finally, HC Wainwright upped their price target on shares of Innate Pharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $6.67.

Innate Pharma Stock Performance

Shares of Innate Pharma stock traded down $0.06 on Thursday, reaching $1.70. 17,692 shares of the company were exchanged, compared to its average volume of 84,048. The stock’s 50 day moving average price is $1.98 and its 200-day moving average price is $1.75. Innate Pharma has a 1-year low of $1.17 and a 1-year high of $2.71.

About Innate Pharma

Innate Pharma SA is a biotechnology company headquartered in Marseille, France, focused on developing immunotherapies for cancer. Founded in 1999, the company uses its expertise in the biology of natural killer cells and other components of the innate immune system to develop antibody-based treatments designed to help the immune system recognize and attack cancer cells.

Innate Pharma’s pipeline includes lacutamab, an investigational antibody targeting KIR3DL2 for certain forms of cutaneous T-cell lymphoma and other T-cell malignancies.